Aktienanalyse zu Capricor Therapeutics, Inc. (CAPR)CAPRCapricor Therapeutics, Inc.

Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program focuses on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, Deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. The clinical development program for Deramiocel has focused primarily on adolescents and young adults with DMD, including many patients who are non-ambulatory and experiencing progressive cardiac and skeletal muscle decline. Its StealthX exosome platform program consists of engineered exosomes for vaccine and therapeutic development. The StealthX vaccine is a proprietary vaccine developed internally utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Capricor Therapeutics Inc is currently not a strong buy due to its high risk factors, despite some positive catalysts. The current price is $7.83, with a significant year-to-date decline of 72.34%. The RSI is at 35.586, indicating that the stock is oversold, but it also reflects a lack of momentum. The upcoming FDA decision on November 22 could be a major catalyst, but the market sentiment is cautious, with analysts predicting a potential drop in stock price. The main risk is the negative sentiment surrounding the FDA's likely response, which could lead to further declines.

1 analysts cover CAPR: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 51.57.